Decanoyl-RVKR-CMK

Cat. No.:	HY-107760
CAS No.:	150113-99-8
Molecular Formula:	$C_{34}H_{66}ClN_{11}O_5$
Molecular Weight:	744.41
Target:	HIV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Decanoyl-RVKR-CMK (DecRVKRcmk) inhibits over-expressed gp160 processing and HIV-1 replication[1].
In Vitro	Decanoyl-RVKR-CMK (DecRVKRcmk) inhibits HIV-2_{ROD} replication by blocking envelope glycoprotein precursor processing in the Jurkat lymphocyte cell[1]. Decanoyl-RVKR-CMK (DecRVKRcmk) blocks regulated secretion of VGF[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	HeLaCD4 cells infected with recombinant vaccinia viruses at a multiplicity of infection (MOI) of 5 PFU/mL.
Concentration:	35 and 70 μM.
Incubation Time:	7 days.
Result:	Peptide at 35 μM significantly inhibited ex vivo HIV-1 and HIV-2 replications (70-80% inhibition).

REFERENCES

[1]. B Bahbouhi, et al. Inhibition of HIV-2(ROD) replication in a lymphoblastoid cell line by the alpha1-antitrypsin Portland variant (alpha1-PDX) and the decRVKRcmk peptide: comparison with HIV-1(LAI). Microbes Infect. 2001 Nov;3(13):1073-84.

[2]. Angelo L Garcia, et al. A prohormone convertase cleavage site within a predicted alpha-helix mediates sorting of the neuronal and endocrine polypeptide VGF into the regulated secretory pathway. J Biol Chem. 2005 Dec 16;280(50):41595-608.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA